Regeneron Pharmaceuticals (REGN) Buildings (2010 - 2017)

Regeneron Pharmaceuticals' Buildings history runs 6 years deep, the most recent figure standing at $1.4 billion for Q4 2017.

• On a quarterly basis, Buildings rose 12.77% year-over-year to $1.4 billion in Q4 2017; TTM through Dec 2017 was $1.4 billion, a 12.77% increase from a year earlier, with the FY2017 full-year figure at $1.4 billion, up 12.77% from the prior year.
• Buildings rose to $1.4 billion in Q4 2017 per REGN's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Buildings topped out at $1.4 billion in Q4 2017 and bottomed at $343.4 million in Q4 2013.
• The 5-year median for Buildings is $760.5 million (2015), against an average of $844.5 million.
• Across the five-year window, Buildings jumped 90.61% in 2015 and gained 12.77% in 2017, its largest moves.
• Year by year, Buildings stood at $343.4 million in 2013, then grew by 16.2% to $399.0 million in 2014, then soared by 90.61% to $760.5 million in 2015, then jumped by 68.08% to $1.3 billion in 2016, then rose by 12.77% to $1.4 billion in 2017.
• Per Business Quant, the three latest REGN Buildings figures stand at $1.4 billion (Q4 2017), $1.3 billion (Q4 2016), and $760.5 million (Q4 2015).